Laboratorios Farmacéuticos ROVI

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

MoneyHero

MCap

USD60m

Last close

USD2.35

▲ 0.55 (30.56%)

MGI – Media and Games Invest

MCap

EUR235m

Last close

EUR1.50

▲ 0.35 (30.21%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Laboratorios Farmacéuticos ROVI. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
Update

10.03.21

Laboratorios Farmacéuticos ROVI — 2021: A pinnacle year

Healthcare |
Outlook

10.12.20

Laboratorios Farmacéuticos ROVI — All good things come in threes

Healthcare |
Update

11.11.20

ROVI Laboratorios Farmaceuticos — Momentum continues across key franchises

Healthcare |
Update

29.07.20

Laboratorios Farmacéuticos ROVI — Top-line growth, significant margin expansion

Visit Website

Sector

Healthcare

Financials

Previously published reports can still be accessed via our website.

Update

Healthcare

06.03.19

Laboratorios Farmacéuticos ROVI — Strength in heparins; next up DORIA

Update

Healthcare

14.11.18

ROVI Laboratorios Farmaceuticos — Becat on track; guidance uplifted

Update

Healthcare

30.07.18

Laboratorios Farmacéuticos ROVI — Top-line strength as R&D costs rise

Outlook

Healthcare

09.05.18

ROVI Laboratorios Farmaceuticos — DORIA low risk, high reward

Update

Healthcare

27.04.18

ROVI Laboratorios Farmaceuticos — Stunning growth in speciality pharmaceuticals

QuickView

27.02.18

Laboratorios Farmacéuticos ROVI — Steady as she grows

Update

Healthcare

14.11.17

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

Laboratorios Farmacéuticos ROVI (SP: ROVI)

Latest Insights

Laboratorios Farmacéuticos ROVI — 2021: A pinnacle year

Laboratorios Farmacéuticos ROVI — All good things come in threes

ROVI Laboratorios Farmaceuticos — Momentum continues across key franchises

Laboratorios Farmacéuticos ROVI — Top-line growth, significant margin expansion

Sector

Financials

Laboratorios Farmacéuticos ROVI — Strength in heparins; next up DORIA

ROVI Laboratorios Farmaceuticos — Becat on track; guidance uplifted

Laboratorios Farmacéuticos ROVI — Top-line strength as R&D costs rise

ROVI Laboratorios Farmaceuticos — DORIA low risk, high reward

ROVI Laboratorios Farmaceuticos — Stunning growth in speciality pharmaceuticals

Laboratorios Farmacéuticos ROVI — Steady as she grows

ROVI Laboratorios Farmaceuticos — Biosimilar enoxaparin launches